| Overview |
| bs-4236R-APC |
| ADAM17 Polyclonal Antibody, APC Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Dog, Cow, Pig, Rabbit |
| Specifications |
| APC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ADAM17 |
| 201-300/824 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 6868 |
| P78536 |
| Cell membrane |
| CSVP; TACE; NISBD; ADAM18; CD156B; NISBD1; Disintegrin and metalloproteinase domain-containing protein 17; ADAM 17; Snake venom-like protease; TNF-alpha convertase; TNF-alpha-converting enzyme; ADAM17 |
| Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz